Pew
Recommendations:
We
recommend that the Secretary of Health and Human Services direct the
Commissioner of the FDA to take steps to
consistently collect reliable and timely information in FDA’s
existing databases on inspections and enforcement actions associated
with compounded drugs, and clearly
differentiate in FDA’s database, those manufacturers of FDA approved drugs
that FDA inspects for compliance with good manufacturing
practices from those entities compounding drugs that are not FDA-approved and
that FDA does not routinely inspect.See full report
http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Other_Resource/Compounding_report.pdf
No comments:
Post a Comment